Published in J Clin Invest on January 02, 2013
Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest (2013) 2.06
Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res (2013) 1.72
Structure of a mammalian ryanodine receptor. Nature (2014) 1.61
Cardiomyocyte protein trafficking: Relevance to heart disease and opportunities for therapeutic intervention. Trends Cardiovasc Med (2014) 1.46
Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal Dilated Cardiomyopathy in Mice. PLoS One (2016) 1.41
Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest (2015) 1.38
Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest (2014) 1.24
Mitochondrial calcium overload is a key determinant in heart failure. Proc Natl Acad Sci U S A (2015) 1.24
STRIPAK complexes: structure, biological function, and involvement in human diseases. Int J Biochem Cell Biol (2013) 1.13
Role of RyR2 phosphorylation in heart failure and arrhythmias: Controversies around ryanodine receptor phosphorylation in cardiac disease. Circ Res (2014) 1.06
Functional role of Calstabin2 in age-related cardiac alterations. Sci Rep (2014) 0.99
The NO/ONOO-cycle as the central cause of heart failure. Int J Mol Sci (2013) 0.94
Systems pharmacology augments drug safety surveillance. Clin Pharmacol Ther (2014) 0.91
Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol (2015) 0.89
Mimicking isovolumic contraction with combined electromechanical stimulation improves the development of engineered cardiac constructs. Tissue Eng Part A (2014) 0.89
Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. J Clin Invest (2014) 0.89
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res (2015) 0.89
cAMP and Ca²⁺ signaling in secretory epithelia: crosstalk and synergism. Cell Calcium (2014) 0.88
Cardiovascular science: opportunities for translating research into improved care. J Clin Invest (2013) 0.88
Structural dynamics and topology of phosphorylated phospholamban homopentamer reveal its role in the regulation of calcium transport. Structure (2013) 0.88
Targeting cardiomyocyte Ca2+ homeostasis in heart failure. Curr Pharm Des (2015) 0.87
Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways. Proc Natl Acad Sci U S A (2014) 0.87
Pak1 is required to maintain ventricular Ca²⁺ homeostasis and electrophysiological stability through SERCA2a regulation in mice. Circ Arrhythm Electrophysiol (2014) 0.87
The case for inhibiting p38 mitogen-activated protein kinase in heart failure. Front Pharmacol (2015) 0.84
Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases. Br J Pharmacol (2015) 0.84
Retracted Oxidative stress and ca(2+) release events in mouse cardiomyocytes. Biophys J (2014) 0.83
Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators. Front Mol Biosci (2014) 0.82
Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations. J Cell Mol Med (2015) 0.81
Three-dimensional cardiac computational modelling: methods, features and applications. Biomed Eng Online (2015) 0.80
Cardiac contractility modulation therapy in advanced systolic heart failure. Nat Rev Cardiol (2013) 0.80
Regulatory role of regucalcin in heart calcium signaling: Insight into cardiac failure (Review). Biomed Rep (2014) 0.80
Postextrasystolic blood pressure potentiation predicts poor outcome of cardiac patients. J Am Heart Assoc (2014) 0.80
PHD2/3-dependent hydroxylation tunes cardiac response to β-adrenergic stress via phospholamban. J Clin Invest (2015) 0.79
Functional cardiac imaging by random access microscopy. Front Physiol (2014) 0.79
Synthetic phosphopeptides enable quantitation of the content and function of the four phosphorylation states of phospholamban in cardiac muscle. J Biol Chem (2014) 0.79
Epicardial Fat: Physiological, Pathological, and Therapeutic Implications. Cardiol Res Pract (2016) 0.79
Norepinephrine-Induced Adrenergic Activation Strikingly Increased the Atrial Fibrillation Duration through β1- and α1-Adrenergic Receptor-Mediated Signaling in Mice. PLoS One (2015) 0.79
Restoration of Mitochondrial Cardiolipin Attenuates Cardiac Damage in Swine Renovascular Hypertension. J Am Heart Assoc (2016) 0.78
Heart failure-specific changes in protein kinase signalling. Pflugers Arch (2014) 0.78
Cardiac ryanodine receptor activation by a high Ca²⁺ store load is reversed in a reducing cytoplasmic redox environment. J Cell Sci (2014) 0.78
Myricitrin Alleviates Oxidative Stress-induced Inflammation and Apoptosis and Protects Mice against Diabetic Cardiomyopathy. Sci Rep (2017) 0.78
Chronic heart failure: Ca(2+), catabolism, and catastrophic cell death. Biochim Biophys Acta (2016) 0.77
Sarcolipin and phospholamban inhibit the calcium pump by populating a similar metal ion-free intermediate state. Biochem Biophys Res Commun (2015) 0.77
Ca2+-binding motif of βγ-crystallins. J Biol Chem (2014) 0.77
Short‑term vagal nerve stimulation improves left ventricular function following chronic heart failure in rats. Mol Med Rep (2015) 0.77
Complement Destabilizes Cardiomyocyte Function In Vivo after Polymicrobial Sepsis and In Vitro. J Immunol (2016) 0.77
Expression of sarco (endo) plasmic reticulum calcium ATPase (SERCA) system in normal mouse cardiovascular tissues, heart failure and atherosclerosis. Biochim Biophys Acta (2014) 0.77
Increased Short-Term Beat-to-Beat QT Interval Variability in Patients with Impaired Glucose Tolerance. Front Endocrinol (Lausanne) (2017) 0.76
The sarcomeric M-region: a molecular command center for diverse cellular processes. Biomed Res Int (2015) 0.76
Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca(2+) cycling proteins. J Transl Med (2014) 0.76
Lack of Gαi2 leads to dilative cardiomyopathy and increased mortality in β1-adrenoceptor overexpressing mice. Cardiovasc Res (2015) 0.76
Ca²⁺ in the cleft: fast and fluorescent. Circ Res (2014) 0.76
Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants. Open Cardiovasc Med J (2016) 0.75
Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy. Biophys Rev (2015) 0.75
Phospholamban Ablation Using CRISPR/Cas9 System Improves Mortality in a Murine Heart Failure Model. PLoS One (2016) 0.75
Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure. World J Cardiol (2016) 0.75
Effects of stachydrine on norepinephrine-induced neonatal rat cardiac myocytes hypertrophy and intracellular calcium transients. BMC Complement Altern Med (2014) 0.75
Pleiotropic Effects of Myocardial MMP-9 Inhibition to Prevent Ventricular Arrhythmia. Sci Rep (2016) 0.75
The Arrhythmogenic Calmodulin Mutation D129G Dysregulates Cell Growth, Calmodulin-dependent Kinase II Activity and Cardiac Function in Zebrafish. J Biol Chem (2016) 0.75
Expression of connexin 43, ion channels and Ca(2+)-handling proteins in rat pulmonary vein cardiomyocytes. Exp Ther Med (2016) 0.75
Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol (2016) 0.75
Melusin Promotes a Protective Signal Transduction Cascade in Stressed Hearts. Front Mol Biosci (2016) 0.75
Pharmacological implications of the Ca(2+)/cAMP signaling interaction: from risk for antihypertensive therapy to potential beneficial for neurological and psychiatric disorders. Pharmacol Res Perspect (2015) 0.75
Optical Mapping of Intra-Sarcoplasmic Reticulum Ca2+ and Transmembrane Potential in the Langendorff-perfused Rabbit Heart. J Vis Exp (2015) 0.75
Luteolin improves cardiac dysfunction in heart failure rats by regulating sarcoplasmic reticulum Ca(2+)-ATPase 2a. Sci Rep (2017) 0.75
Calstabin 2: An important regulator for learning and memory in mice. Sci Rep (2016) 0.75
Chronic Contractile Dysfunction without Hypertrophy Does Not Provoke a Compensatory Transcriptional Response in Mouse Hearts. PLoS One (2016) 0.75
Carbon monoxide pollution aggravates ischemic heart failure through oxidative stress pathway. Sci Rep (2017) 0.75
S100A1 Protein Does Not Compete with Calmodulin for Ryanodine Receptor Binding but Structurally Alters the Ryanodine Receptor·Calmodulin Complex. J Biol Chem (2016) 0.75
17ß-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodeling. PLoS One (2015) 0.75
Extract of Sheng-Mai-San Ameliorates Myocardial Ischemia-Induced Heart Failure by Modulating Ca(2+)-Calcineurin-Mediated Drp1 Signaling Pathways. Int J Mol Sci (2017) 0.75
Identification of transcriptome signature for myocardial reductive stress. Redox Biol (2017) 0.75
Phosphorylation of serine96 of histidine-rich calcium-binding protein by the Fam20C kinase functions to prevent cardiac arrhythmia. Proc Natl Acad Sci U S A (2017) 0.75
Sex-specific cardiovascular responses to control or high fat diet feeding in C57bl/6 mice chronically exposed to bisphenol A. Toxicol Rep (2015) 0.75
Loss of MD1 exacerbates pressure overload-induced left ventricular structural and electrical remodelling. Sci Rep (2017) 0.75
Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med (2006) 49.95
PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell (2000) 10.25
FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell (2003) 4.68
Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell (1994) 4.26
Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science (2004) 3.45
Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med (2009) 3.27
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell (2005) 3.01
Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest (2009) 2.98
Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci U S A (2006) 2.81
Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation (2004) 2.69
Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ Res (2001) 2.67
Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation (2003) 2.57
FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation (2003) 2.57
Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest (2003) 2.56
Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest (2008) 2.45
Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res (2003) 2.44
Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab (2011) 2.06
Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation (2001) 2.02
Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation (2000) 2.01
Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. Proc Natl Acad Sci U S A (2005) 1.99
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol (2011) 1.89
Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc Natl Acad Sci U S A (2006) 1.87
Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res (1993) 1.83
PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J Cell Biol (2003) 1.78
Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A (2004) 1.77
Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. J Clin Invest (2010) 1.77
Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J Biol Chem (2002) 1.73
Altered interaction of FKBP12.6 with ryanodine receptor as a cause of abnormal Ca(2+) release in heart failure. Cardiovasc Res (2000) 1.71
Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A (2010) 1.67
Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem (1996) 1.64
Role of CaMKIIdelta phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. Proc Natl Acad Sci U S A (2010) 1.63
Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. J Clin Invest (2010) 1.60
Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res (1999) 1.55
Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res (2012) 1.41
Ryanodine receptor S2808 phosphorylation in heart failure: smoking gun or red herring. Circ Res (2012) 1.31
Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am J Physiol Heart Circ Physiol (2003) 1.24
beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation (2001) 1.23
Increased Ca(2+) leak and spatiotemporal coherence of Ca(2+) release in cardiomyocytes during beta-adrenergic stimulation. J Physiol (2009) 1.22
Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med (2010) 1.20
Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol (1999) 1.17
Ca2+ cycling and new therapeutic approaches for heart failure. Circulation (2010) 1.16
A guide for the perplexed: towards an understanding of the molecular basis of heart failure. Circulation (2003) 1.14
Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: rescue of heart failure by calstabin2 in mice. Proc Natl Acad Sci U S A (2006) 1.13
Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model. Circ J (2010) 1.12
The ryanodine receptor from canine heart sarcoplasmic reticulum is associated with a novel FK-506 binding protein. Biochem Biophys Res Commun (1994) 1.12
Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation (2002) 1.12
A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol (2002) 1.12
Constitutive cardiac overexpression of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation (2004) 1.12
Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation (1990) 1.10
The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol (2010) 1.09
Ryanodine receptor leak mediated by caspase-8 activation leads to left ventricular injury after myocardial ischemia-reperfusion. Proc Natl Acad Sci U S A (2011) 1.05
Fixing ryanodine receptor Ca leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov Today Dis Mech (2010) 1.04
Effects of JTV-519, a novel anti-ischaemic drug, on the delayed rectifier K+ current in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol (2000) 0.99
A mechanism of ryanodine receptor modulation by FKBP12/12.6, protein kinase A, and K201. Cardiovasc Res (2010) 0.98
Expression of the sarco/endoplasmic reticulum calcium ATPase type 2 and 3 isoforms in normal skin and Darier's disease. Br J Dermatol (2004) 0.96
Protein kinase A-dependent phosphorylation of ryanodine receptors increases Ca2+ leak in mouse heart. Biochem Biophys Res Commun (2009) 0.93
Inhibition of annexin V-dependent Ca2+ movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative. Biochim Biophys Acta (1997) 0.92
Ryanodine receptor studies using genetically engineered mice. FEBS Lett (2010) 0.92
Dysregulated ryanodine receptors mediate cellular toxicity: restoration of normal phenotype by FKBP12.6. J Biol Chem (2003) 0.91
Differentiation-dependent expression of cardiac delta-CaMKII isoforms. J Cell Biochem (1998) 0.87
JTV-519, a novel cardioprotective agent, improves the contractile recovery after ischaemia-reperfusion in coronary perfused guinea-pig ventricular muscles. Br J Pharmacol (2000) 0.87
Congestive heart failure: pathophysiologic consequences of neurohormonal activation and the potential for recovery: part II. Am J Med Sci (2011) 0.80
Contemporary management and research directions in advanced heart failure: where are we going? Congest Heart Fail (2011) 0.79
Neurohormonal activation and exercise function in patients with severe heart failure and patients with left ventricular assist system. A comparative study. Chest (1995) 0.78